Go big or go home, seems to be the message of Coherus’ President Dennis Lanfear. At the JP Morgan Investor Conference yesterday in San Francisco, he outlined what he considers a “full-on branded launch” for the biosimilar maker’s key product. Udenyca was officially launched on January 3. In preparation for the launch of Udenyca, Coherus … Continue reading More Details on Coherus Bioscience’s Udenyca Launch
Tag: Denny Lanfear
Udenyca to Launch January 3, Same WAC as Mylan’s Fulphila
Coherus Biosciences surprised many on its third-quarter earnings call late yesterday. It will rely not on a lower price than its biosimilar competitor to gain marketshare after Coherus' Udenyca launch, but on its ability to pull through on its patient and provider services and supply chain to gain significant marketshare for its biosimilar version of … Continue reading Udenyca to Launch January 3, Same WAC as Mylan’s Fulphila